Bristol-Myers Squibb Co (BMY) : Verus Financial Partners added new position in Bristol-Myers Squibb Co during the most recent quarter end. The investment management firm now holds 2,961 shares of Bristol-Myers Squibb Co which is valued at $224,918 , the company said in a statement filed on Jul 15, 2016 with the SEC.Bristol-Myers Squibb Co makes up approximately 0.10% of Verus Financial Partners’s portfolio.
Other Hedge Funds, Including , Peddock Capital Advisors reduced its stake in BMY by selling 200 shares or 3.07% in the most recent quarter. The Hedge Fund company now holds 6,308 shares of BMY which is valued at $479,156. Bristol-Myers Squibb Co makes up approx 0.30% of Peddock Capital Advisors’s portfolio.Naples Global Advisors boosted its stake in BMY in the latest quarter, The investment management firm added 500 additional shares and now holds a total of 15,086 shares of Bristol-Myers Squibb Co which is valued at $1,155,286. Bristol-Myers Squibb Co makes up approx 0.46% of Naples Global Advisors’s portfolio.Franklin Street Advisors Inc Nc boosted its stake in BMY in the latest quarter, The investment management firm added 578 additional shares and now holds a total of 117,527 shares of Bristol-Myers Squibb Co which is valued at $9,000,218. Bristol-Myers Squibb Co makes up approx 1.66% of Franklin Street Advisors Inc Nc’s portfolio.Macnealy Hoover Investment Management Inc reduced its stake in BMY by selling 998 shares or 5.24% in the most recent quarter. The Hedge Fund company now holds 18,052 shares of BMY which is valued at $1,358,955. Bristol-Myers Squibb Co makes up approx 0.26% of Macnealy Hoover Investment Management Inc’s portfolio.Osborn Rohs Williams Donohoe Ltd reduced its stake in BMY by selling 81 shares or 0.13% in the most recent quarter. The Hedge Fund company now holds 61,019 shares of BMY which is valued at $4,593,510. Bristol-Myers Squibb Co makes up approx 0.88% of Osborn Rohs Williams Donohoe Ltd’s portfolio.
Bristol-Myers Squibb Co closed down -0.04 points or -0.05% at $75.96 with 37,94,127 shares getting traded on Monday. Post opening the session at $76.27, the shares hit an intraday low of $75.62 and an intraday high of $76.36 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.65. The company had revenue of $4391.00 million for the quarter, compared to analysts expectations of $4268.65 million. The company’s revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.71 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co was Initiated by Hilliard Lyons to “Neutral” on May 23, 2016. Company shares were Reiterated by UBS on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 80 from a previous price target of $73 .Company shares were Reiterated by Barclays on Apr 29, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 75 from a previous price target of $70 .
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.